AffaMed In-licenses Rights to AMD Therapy, Approved to Start US Trials
publication date: Feb 15, 2022
Shanghai AffaMed recently in-licensed ex-Asia (plus Japan) rights to a novel bispecific biologic molecule aimed at retinal vascular diseases from AskGene Pharma, located west of Los Angeles. Today, AffaMed announced US approval to start clinical trials of the candidate, AM712, a dual inhibitor of vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), in patients with neovascular AMD. AffaMed will have exclusive rights to develop, manufacture and commercialize AM712 in the territories. Further details of the agreement were not disclosed. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.